Search research articles
Contact Us
Filters
Showing results (331-340 of 420) with videos related to
Page
of 42
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 21, 2005
Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program
Thomas R Fritsche, Helio S Sader, Mark A Toleman, et al.
Diagnostic Microbiology and Infectious Disease
|
January 24, 2006
Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004)
Ronald N Jones, Matthew G Stilwell, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy
|
December 15, 2007
Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa
Judy N Chin, Ronald N Jones, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy
|
June 11, 2004
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations
Ronald N Jones, Holly K Huynh, Douglas J Biedenbach, et al.
Antimicrobial Agents and Chemotherapy
|
December 22, 2017
Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers
Helio S Sader, Rodrigo E Mendes, Leonard R Duncan, et al.
International Journal of Antimicrobial Agents
|
February 8, 2018
Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016)
Michael A Pfaller, Michael D Huband, Jennifer M Streit, et al.
Journal of Clinical Microbiology
|
January 12, 2007
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
Douglas J Biedenbach, James E Ross, Thomas R Fritsche, et al.
Journal of Chemotherapy (Florence, Italy)
|
October 16, 2013
Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value
Robert K Flamm, Gregory G Stone, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy
|
November 3, 2014
Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13)
Rodrigo E Mendes, David J Farrell, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
August 21, 2016
Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013-2014)
Leonard R Duncan, Helio S Sader, Robert K Flamm, et al.
Page
of 42
Search research articles
Search
Showing results (331-340 of 420) with videos related to
Sort By:
Page
of 42
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 21, 2005
Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program
Thomas R Fritsche, Helio S Sader, Mark A Toleman, et al.
Diagnostic Microbiology and Infectious Disease
|
January 24, 2006
Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004)
Ronald N Jones, Matthew G Stilwell, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy
|
December 15, 2007
Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa
Judy N Chin, Ronald N Jones, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy
|
June 11, 2004
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations
Ronald N Jones, Holly K Huynh, Douglas J Biedenbach, et al.
Antimicrobial Agents and Chemotherapy
|
December 22, 2017
Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers
Helio S Sader, Rodrigo E Mendes, Leonard R Duncan, et al.
International Journal of Antimicrobial Agents
|
February 8, 2018
Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016)
Michael A Pfaller, Michael D Huband, Jennifer M Streit, et al.
Journal of Clinical Microbiology
|
January 12, 2007
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
Douglas J Biedenbach, James E Ross, Thomas R Fritsche, et al.
Journal of Chemotherapy (Florence, Italy)
|
October 16, 2013
Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value
Robert K Flamm, Gregory G Stone, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy
|
November 3, 2014
Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13)
Rodrigo E Mendes, David J Farrell, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
August 21, 2016
Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013-2014)
Leonard R Duncan, Helio S Sader, Robert K Flamm, et al.
Page
of 42